Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 3/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979402 | 0.83 | SMO (0.50) | DHODHFABP4KDM4EALDH1A1HPGD | |
| SCHEMBL5099992 | 0.83 | FABP4 (0.49) | DHODHKIF11FABP4CYP2C8ALDH1A1 | |
| SCHEMBL135115 | 0.83 | SMO (0.50) | DHODHFABP4KDM4EALDH1A1HPGD | |
| SCHEMBL6705895 | 0.82 | CFTR (0.48) | TTRKDM4EALDH1A1HPGDADAMTS7 | |
| Hydrochloric Acid SCHEMBL6200222 | 0.81 | SMO (0.49) | FABP4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23354172 | 0.81 | CYP2C8 (0.47) | KIF11CYP2C8KDM4EALDH1A1HPGD | |
| SCHEMBL10644876 | 0.80 | MRGPRX4 (0.49) | DHODHKIF11FABP4CYP2C8KDM4E | |
| SCHEMBL593550 | 0.80 | TTR (0.56) | TTRDHODHALBFABP4KDM4E | |
| SCHEMBL6708229 | 0.79 | RXRA (0.40) | DHODHKIF11FABP4CYP2C8KDM4E | |
| SCHEMBL6501691 | 0.79 | FABP3 (0.52) | FABP4KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822268-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2021-05-19 | — | — | EP | disclosed |
| EP-3822268-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2021-05-19 | — | — | EP | disclosed |
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-05 | — | — | US | disclosed |
| WO-2003048121-A1 | THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | APOB, APOL1, CETP | TTR 25/4885DHODH 3608/4885ALB 85/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | TTR 2652/4885DHODH 2304/4885ALB 4760/4885 |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | TTR 2652/4885DHODH 2304/4885ALB 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.